151004-88-5 Usage
Uses
Used in Scientific Research:
(R)-N-Cbz-3,4-Dihydro-1H-isoquinolinecarboxylic acid is used as an intermediate compound for the synthesis of more complex organic compounds, facilitating the development of new chemical entities and materials in the field of chemistry.
Used in Pharmaceutical Industry:
(R)-N-Cbz-3,4-Dihydro-1H-isoquinolinecarboxylic acid is used as a building block in the synthesis of pharmaceutical compounds, contributing to the creation of new drugs and therapeutic agents.
Used in Chemical Synthesis:
(R)-N-Cbz-3,4-Dihydro-1H-isoquinolinecarboxylic acid is used as a reagent in various chemical reactions, enabling the production of a wide range of chemical products with potential applications in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 151004-88-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,1,0,0 and 4 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 151004-88:
(8*1)+(7*5)+(6*1)+(5*0)+(4*0)+(3*4)+(2*8)+(1*8)=85
85 % 10 = 5
So 151004-88-5 is a valid CAS Registry Number.
InChI:InChI=1/C18H17NO4/c20-17(21)16-15-9-5-4-8-14(15)10-11-19(16)18(22)23-12-13-6-2-1-3-7-13/h1-9,16H,10-12H2,(H,20,21)/t16-/m1/s1
151004-88-5Relevant academic research and scientific papers
Enantioselective addition of vinylzinc reagents to 3,4-dihydroisoquinoline N-oxide
Wang, Sa,Seto, Christopher T.
, p. 3979 - 3982 (2007/10/03)
Ligand 2a promotes the enantioselective addition of vinylzinc reagents to 3,4-dihydroisoquinoline N-oxide to yield chiral allylic hydroxylamines. With 0.1 equiv of the ligand, the product is obtained in up to 84% ee, whereas with 1.2 equiv of the ligand,
PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
-
Page 55, (2008/06/13)
GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure formula (I) wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
